The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Daiichi Sankyo’s Quizartinib Accepted for European Review in 1st Line AML
Daiichi Sankyo said on August 23 that an application for its FLT3 inhibitor quizartinib was accepted for review by European regulatory authorities for the first-line treatment of certain patients with newly diagnosed acute myeloid leukemia (AML). The drug, known as…
To read the full story
Related Article
- Daiichi Sankyo’s FLT3 Inhibitor Gets EU Approval for 1st Line AML
November 10, 2023
- European Panel Backs Enhertu Label Expansion, Quizartinib: Daiichi Sankyo
September 20, 2023
- Daiichi Sankyo Bags FDA Nod for FLT3 Inhibitor in 1st Line AML
July 24, 2023
- US FDA Extends Target Date for Daiichi Sankyo’s FLT3 Inhibitor by 3 Months
April 24, 2023
- Daiichi Sankyo’s FLT3 Inhibitor Gets FDA’s Priority Review for 1st Line AML
October 26, 2022
- Quizartinib Cuts Risk of Death by 22.4% in 1st Line AML: Daiichi Sankyo
June 14, 2022
- European Panel Snubs Daiichi Sankyo’s Quizartinib
October 21, 2019
- Daiichi Sankyo’s AML Drug Vanflyta Now Available
October 11, 2019
- Days after Japan OK, FDA Spurns Daiichi Sankyo’s Quizartinib
June 25, 2019
BUSINESS
- Sanofi Bets on Immunotherapy to Delay Onset of Type 1 Diabetes
December 19, 2025
- Japan’s 1st Eylea Biosimilar to Reach Market on January 7
December 19, 2025
- Padcev-Keytruda Pair Makes Mark in Cisplatin-Eligible MIBC: Astellas
December 19, 2025
- Daiichi Sets February Launch for Japan’s 1st OTC Morning-After Pill
December 19, 2025
- Takeda’s TYK2 Inhibitor Scores PIII Win in Psoriasis Trials, Tops Otezla on Key Metrics
December 19, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…